Portable electrochemical immunosensor for point-of-care testing of ovarian cancer biomarker HE4 in commercial human blood serum samples.

Merve Yılmaz Çılçar, Melike Bilgi Kamaç

Abstract read

In one paragraph

Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Merve Yılmaz ÇılçarChemistry Department, Faculty of Science, Çankırı Karatekin University, Çankırı, 18100, Türkiye.

Melike Bilgi KamaçChemistry Department, Faculty of Science, Çankırı Karatekin University, Çankırı, 18100, Türkiye. melikesahin@karatekin.edu.tr.

Funding

Çankırı Karatekin University Scientific Research Projects Coordinator EY0211221D07Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 222Z121

6 · The paper itself

Abstract

Ovarian cancer ranks as the seventh most prevalent malignancy among women globally. Human epididymis protein 4 (HE4) is an FDA-approved tumor biomarker for the early detection of malignant ovarian cancer. In this work, a portable, electrochemical HE4 immunosensor was fabricated for the rapid, sensitive, and practical analysis of HE4 levels in commercial human blood serum. In the preparation of immunosensors, nanomaterials such as Ti

Indexed as

Biomarkers, TumorBiosensing TechniquesElectrochemical TechniquesOvarian NeoplasmsPoint-of-Care TestingProteinsFemaleGoldHumansImmunoassayLimit of DetectionMetal NanoparticlesWAP Four-Disulfide Core Domain Protein 2Biomarkers, TumorGoldProteinsWAP Four-Disulfide Core Domain Protein 2WFDC2 protein, humanAuNPOvarian cancerPoint-of-care testingPortable HE4 immunosensorTi3C2Ti3C2-COOH

Identifiers

PMID41904742

DOI10.1007/s00216-026-06457-7

PMCPMC13197341

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.